Mdr1 Transfection Causes Enhanced Apoptosis by Paclitaxel: An Effect Independent of Drug Efflux Function of P-Glycoprotein

[1]  J. Au,et al.  Apoptosis: A New Pharmacodynamic Endpoint , 1997, Pharmaceutical Research.

[2]  N. Millenbaugh,et al.  Cytostatic and Apoptotic Effects of Paclitaxel in Human Ovarian Tumors , 2004, Pharmaceutical Research.

[3]  L. Kèlland,et al.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[4]  M. Wientjes,et al.  Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.

[5]  M. Wientjes,et al.  Relationship between paclitaxel activity and pathobiology of human solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Jie Lu,et al.  Cytostatic and apoptotic effects of paclitaxel in human breast tumors , 1998, Cancer Chemotherapy and Pharmacology.

[7]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[8]  G. Giaccone,et al.  Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. , 1998, Oncology reports.

[9]  J. L. Au,et al.  Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumors. , 1997, Urologic oncology.

[10]  John Calvin Reed,et al.  Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells , 1997, Leukemia.

[11]  A. Monks,et al.  Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration , 1997, Cancer Chemotherapy and Pharmacology.

[12]  Jessie L.-S. Au,et al.  Pharmacologic effects of paclitaxel in human bladder tumors , 1997, Cancer Chemotherapy and Pharmacology.

[13]  M. Wientjes,et al.  Pharmacodynamics of taxol in human head and neck tumors. , 1996, Cancer research.

[14]  T. Skovsgaard,et al.  Cellular resistance to anthracyclines. , 1996, General pharmacology.

[15]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[16]  F. Nathan,et al.  Gene therapy for human cancer: an essay for clinicians. , 1996, Seminars in oncology.

[17]  G. Hortobagyi,et al.  Single-agent paclitaxel for the treatment of breast cancer: an overview. , 1996, Seminars in oncology.

[18]  M. Haber,et al.  Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) , 1995, The Journal of Biological Chemistry.

[19]  M. Relling,et al.  Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.

[20]  K. Bhalla,et al.  Characterization of a human myeloid leukemia cell line highly resistant to taxol. , 1994, Leukemia.

[21]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  O. Fardel,et al.  Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. , 1993, Blood.

[23]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[24]  B. Monsarrat,et al.  Taxol: pharmacology, metabolism and clinical implications. , 1993, Cancer surveys.

[25]  G. Peters,et al.  Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. , 1992, British Journal of Cancer.

[26]  K. Danenberg,et al.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.

[27]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[28]  K. Cowan,et al.  Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. , 1990, Molecular pharmacology.

[29]  M. Tanimoto,et al.  Increased P‐glycoprotein expression and multidrug‐resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage , 1989, Cancer.

[30]  伊藤 良則.  Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells sequential analysis of 15 cases at initial presentation and relapsed stage , 1989 .

[31]  I. Ringel,et al.  Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. , 1987, The Journal of pharmacology and experimental therapeutics.

[32]  W. Mellado,et al.  Taxol: mechanisms of action and resistance. , 1986, Annals of the New York Academy of Sciences.

[33]  P. Schiff,et al.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. , 1981, Biochemistry.